|
Synonyms: HM-12525A | HM12525A | JNJ-64565111 | JNJ64565111 | LAPS-GLP-1/GCG | MK-6024 | MK6024
Compound class:
Peptide
Comment: Efinopegdutide (MK-6024, formerly HM-12525A and JNJ-64565111) is a once-weekly injectable, dual agonist of the GLP-1 and glucagon receptors [3]. Structurally is a conjugate of an oxyntomodulin analogue and the constant region (Fc) of human IgG4, joined via a 10 kDa polyethylene glycol (PEG) linker. The INN record shows that the amino acid sequence of the oxyntomodulin analogue component is HBQGTFTSDYSKYLDEKRAKEFVQWLMNTC-NH2, where B2 is 2-methylalanyl (2-aminoisobutyryl, Aib). An amide bond between E and K cyclises the peptide.
|
| References |
|
1. Alba M, Yee J, Frustaci ME, Samtani MN, Fleck P. (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clin Obes, 11 (2): e12432. [PMID:33475255] |
|
2. Di Prospero NA, Yee J, Frustaci ME, Samtani MN, Alba M, Fleck P. (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study. Clin Obes, 11 (2): e12433. [PMID:33475251] |
|
3. Kim JK, Park YJ, Choi JP, Jung SY. (2020)
Glucagon derivative and a composition comprising a long acting conjugate of the same. Patent number: US10696725B2. Assignee: Hanmi Pharmaceutical Co Ltd. Priority date: 29/06/2016. Publication date: 30/06/2020. |
|
4. Lawitz E, Wong VW, Shankar RR, Francque S, Patel K, Miele L, Abdelmalek MF, Krishnan R, Zhang Z, Lam RLH et al.. (2026)
Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet, [Epub ahead of print]. [PMID:43003105] |
|
5. Moiz A, Filion KB, Samuels AE, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. (2026)
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review. Ann Intern Med, 179 (10): 1412-1429. [PMID:42673585] |
|
6. Novikoff A, Müller TD. (2023)
The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides, 165: 171003. [PMID:36997003] |
|
7. Polyzos SA, Frühbeck G, Kiortsis DN. (2023)
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease. Curr Pharm Des, 29 (41): 3263-3265. [PMID:38111116] |
|
8. Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS, MK-6024 P001 Study Group. (2023)
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol, 79 (4): 888-897. [PMID:37355043] |
|
9. Sookoian S, Pirola CJ. (2026)
Efinopegdutide: a step towards precision in MASH therapy?. Lancet, [Epub ahead of print]. [PMID:43003104] |